NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...
Neomorph is building out its supply of Big Pharma partnerships, this time stamping down an option-to-license pact with AbbVie that centers around the biotech’s molecular glue platform.
As an undisputed immunology industry leader, AbbVie is well-prepared to capitalize on the rapid growth of the entire immunotherapy market. Moreover, it's both new superstar immunology products ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback